Kite submits biologics license application to US FDA for KTE-X19
KTE-X19 is an investigational, autologous, anti-CD19 CAR T cell therapy that uses the XLP manufacturing process
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Dec 19
KTE-X19 is an investigational, autologous, anti-CD19 CAR T cell therapy that uses the XLP manufacturing process
11 Dec 19
CF is a rare, progressive, multi-system genetic disease that affects the lungs, liver, GI tract, sinuses, sweat glands,…
The chief executive of the General Pharmaceutical Council says companies supplying prescription drugs online need to be professional…
While e-pharmacies have made obtaining prescription drugs cheaper and easier, MedExpress founder Dwayne D'Souza says patient safety is…
06 Dec 19
Lynparza is an advanced PARP inhibitor, used for treating advanced ovarian cancer and metastatic breast cancer
05 Dec 19
Tecentriq binds with PD-L1, a protein expressed on tumour cells and tumour-infiltrating immune cells, to activate T cells…
04 Dec 19
AstraZeneca will receive $35m in an upfront payment, in addition to the payments of up to $6m contingent…
The new drug differs from many established acute migraine treatments by lowering blood pressure, rather than raising it
02 Dec 19
ViGeneron will use the funds to advance the development of its next-generation ophthalmic gene therapy pipeline and vector…
28 Nov 19
Incyte is seeking approval of pemigatinib for cholangiocarcinoma on the basis of data from the phase 2 FIGHT-202…